The pharmacokinetic profile of oral zidovudine entrapped in a 50:50 polyactide-coglycolide matrix (nanospheres) was compared to those of standard oral and parenteral zidovudine formulations in rabbits. The bioavailability of zidovudine nanospheres at 50 mg/kg of body weight was 76%, and this dose achieved prolonged exposure to zidovudine compared to standard formulations without an increase in the drug's peak concentration.
|Original language||English (US)|
|Number of pages||3|
|Journal||Antimicrobial Agents and Chemotherapy|
|Publication status||Published - 1999|
ASJC Scopus subject areas
- Pharmacology (medical)